NECTIN4, targeted by the FDA-approved ADC enfortumab vedotin2, was expressed with moderate to high intensity (2+ or 3+) in 30.4% of cases, and was restricted to tumor cells, making it a compelling target. This evidence concerns the gene NECTIN4 and neoplasm.